Pulmonary disease in Sjögren s Clinical Practice Guidelines (SF, 2021) medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.
(1)
EUSA Pharma (UK) Limited (
EUSA Pharma ), a global biopharmaceutical company focused on oncology and rare diseases, announced that the National Comprehensive Cancer Network
(NCCN
) for B-Cell Lymphomas to include siltuximab (SYLVANT
) as the preferred primary treatment for patients with human immunodeficiency virus-negative [HIV(-)] and human herpesvirus 8-negative [HHV-8(-)] multicentric Castleman disease (MCD), also known as idiopathic multicentric Castleman disease (iMCD), regardless of histopathologic subtype.
1 Siltuximab is currently approved in more than 40 countries worldwide for the treatment of all histopathologic subtypes of iMCD, a rare, life-threatening and debilitating orphan condition of the lymph nodes and related tissues. 2,3 The update is based on a 2020 publication which demonstrated that there is insufficient evidence to guide treatment based solely on lymph node histopathologic subtype.
StartUPDATES: New developments from healthcare startups medcitynews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medcitynews.com Daily Mail and Mail on Sunday newspapers.
Operator
Good morning. My name is Vaishnavi, and I ll be your conference operator for today. At this time, I would like to welcome everyone to the Karyopharm Therapeutics Fourth Quarter and Full Year 2020 Financial Results Conference Call. There will be a question-and-answer session to follow. [Operator Instructions]
I would now like to turn the call over to Mr. Ian Karp, Karyopharm s Senior Vice President, Investor and Public Relations. Please go ahead.
Ian Karp
Senior Vice President, Investor And Public Relations
Thanks so much. And thank you all for joining us on today s conference call to discuss Karyopharm s fourth quarter and full year 2020 financial results and business update. This is Ian Karp. And I m joined today by Dr. Michael Kauffman, our Chief Executive Officer; Mr. Mike Mason, Chief Financial Officer; Mr. John Demaree, Chief Commercial Officer; Dr. Jatin Shah, Chief Medical Officer; and Mr. Stephen Mitchener, Chief Business Officer. On the call today, Michael
Karyopharm Reports Fourth Quarter and Full Year 2020 Financial Results and Highlights Recent Company Progress Commercial Launch of XPOVIO® (selinexor) In Expanded Multiple Myeloma Indication Fully Underway Following December 18, 2020 FDA Approval XPOVIO Net Product Sales of $20.2 Million for Fourth Quarter 2020 and $76.2 Million for the Year 2020; Total Revenues of $35.1 Million for the Fourth Quarter 2020 and $108.1 Million for the Year 2020 Positive CHMP Opinion for NEXPOVIO® (selinexor) in Penta-Refractory Multiple Myeloma Issued; European Commission Decision Expected by April 2021 Conference Call Scheduled for Today at 8:30 a.m. ET
News provided by
Share this article
Share this article